Reapplix Revenue and Competitors
Estimated Revenue & Valuation
- Reapplix's estimated annual revenue is currently $8M per year.
- Reapplix's estimated revenue per employee is $251,000
Employee Data
- Reapplix has 32 Employees.
- Reapplix grew their employee count by -9% last year.
Reapplix's People
| Name | Title | Email/Phone |
|---|
Reapplix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Reapplix?
Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient's capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Our business model is supported by high quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation. www.reapplix.com
keywords:N/A
N/A
Total Funding
32
Number of Employees
$8M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Reapplix News
... Verpackungsmaschinen GmbH, Sanara MedTech Inc., Reapplix A/S, Cardinal Health, Ostomed, Kerecis, Axio Biosolutions Pvt Ltd, NanoVibronix.
Other Companies in Birkerød
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.6M | 37 | -14% | N/A |
#2 | $7.5M | 130 | 7% | N/A |